FTC eyes crackdown on improper drug patents in FDA's Orange Book
Fierce Pharma
SEPTEMBER 7, 2023
After a clutch of lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book—the registry for patents of approved drugs—the Federal Trade Commission (FTC) is getting in on | After multiple lawmakers last month challenged “sham patents” registered with the FDA’s Orange Book, the FTC is getting in on the action.
Let's personalize your content